The Board of Trustees of Illinois State University approved a contract with Reditus Laboratories for COVID-19 testing.
The five-month contract, at a cost not to exceed $3.3 million, will provide immediate support for surveillance testing. Surveillance testing refers to general testing for anyone not currently suffering COVID-19-like symptoms. This cost estimate provides for up to 30,000 tests being conducted over the contract period ending December 31, 2020, at a projected contract price of $110 per test. Testing will be completed at on-campus locations.
The University already holds a contract with Reditus Laboratories for symptomatic testing services, in which Student Health Services collects test samples for symptomatic students. This new contract is a separate agreement with Reditus Laboratories for surveillance testing.
Reditus Laboratories also partners with the Illinois Department of Public Health to manage the McLean County Interstate Center testing site. Earlier this summer, Reditus Laboratories also conducted COVID-19 testing for Illinois State University athletics to qualify athletes for participation in team practices and events.
The University has implemented several strategies to limit the spread of COVID-19 based on guidance from local, state, and national authorities such as the Centers for Disease Control, the Illinois Department of Public Health, the Illinois Board of Higher Education, and the Governor of the State of Illinois. Consistent with the recommendations of these authorities, the University’s Redbirds Return Plan calls for available COVID-19 testing and contact tracing as a critical element for the return to campus for the fall to allow for the rapid identification and containment of new cases of COVID-19.